венозные тромбоэмболические осложнения, тромбоз глубоких вен, тромбоэмболия легочной артерии, дабигатран, варфарин, антикоагулянты, Internal medicine, RC31-1245

This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC). The article presents the results of 4 randomized clinical studies: RE-COVER, RE-COVER II, RE-MEDY and RESONATE. The RE-COVER and RE-COVER (II) studies compared the effectiveness and safety of dabigatran and warfarin in patients with acute episode of VTC, and RE-MEDY and RESONATE studies assessed the prolongation of dabigatran therapy in patients with VTC, who completed the main 3-6-month course of anticoagulant therapy. In addition, REMEDY study estimated efficacy of dabigatran compared with warfarin, and RE-SONATE study estimated one compared with placebo. RE-COVER, RE-COVER II and RE-MEDY showed that the efficacy of dabigatran (150 mg 2 times a day) for the prevention of recurrent and fatal episodes of VTС was not less than that of warfarin; on top of that, dabigatran was more efficient in reducing the risk of hemorrhag-ic complications. In RE-SONATE study, dabigatran showed a 92% reduction in risk of the VTC relapse compared to placebo, but a 2.9-fold increase in risk of large or small clinically significant bleeding.